• Theme 1: Antigen discovery and antigen-specific immunity across cancers. The data show identification of melanoma-associated antigenic systems, autologous tumor antigens, serological antigen typing, and idiotype-targeted approaches, illustrating both humoral and cellular tumor recognition [5][6][9][13][10][20][15][1].

• Theme 2: Blocking factors and humoral modulation of anti-tumor immunity. Sera from tumor patients can block cytotoxic lymphocyte activity; studies document blocking antibodies, complexes, and elutable blocking factors, indicating soluble modulators of tumor immunity across multiple histologies [3][4][11][19][12].

• Theme 3: Adoptive immunotherapy and in vitro T-cell sensitization with IL-2 support. Lymphocytes expanded from tumors or mice can mediate tumor regression after adoptive transfer or IL-2 cytokine support; clinical pilots and in vitro sensitization show convergence toward tumor-specific cytotoxicity [2][18][16].

• Theme 4: Immune regulation and tumor-induced immunosuppression via suppressor cells. Evidence for tumor-associated immunosuppressor/regulatory cells and their depletion enhances anti-tumor responses, shaping therapeutic strategies that target immune regulation [17][7][14].